Neovasc (NASDAQ:NVCN) (TSE:NVC) is scheduled to announce its earnings results after the market closes on Thursday, March 21st. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.
NASDAQ NVCN traded down $0.02 during trading hours on Thursday, reaching $0.45. 14,217 shares of the stock traded hands, compared to its average volume of 1,764,277. Neovasc has a 1 year low of $0.42 and a 1 year high of $15.50. The company has a market capitalization of $14.80 million, a price-to-earnings ratio of -0.01 and a beta of 1.62.
A number of equities research analysts have weighed in on the company. Zacks Investment Research downgraded Neovasc from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. ValuEngine upgraded Neovasc from a “hold” rating to a “buy” rating in a research report on Friday, March 1st.
Neovasc Company Profile
Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.
Recommended Story: How to invest in blue-chip stocks
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.